BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23342677)

  • 21. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure.
    Walji N; Bhatt L; Dhallu S; Fernando IN
    Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there more for us to learn from oncology?: Examining the implications of anthracycline effects on the young heart.
    Sawyer DB
    Circulation; 2010 Feb; 121(5):623-5. PubMed ID: 20100976
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiac risks in multimodal breast cancer treatment.
    Budach W
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiac testing to manage cardiovascular risk in cancer patients.
    Davis M; Witteles RM
    Semin Oncol; 2013 Apr; 40(2):147-55. PubMed ID: 23540740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 29. Update on administration of adjuvant trastuzumab.
    McArthur HL
    Clin Adv Hematol Oncol; 2010 May; 8(5):321-2, 375. PubMed ID: 20551890
    [No Abstract]   [Full Text] [Related]  

  • 30. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab cardiac side effects: only time will tell.
    Levine MN
    J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 34. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
    Gianni L
    Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
    [No Abstract]   [Full Text] [Related]  

  • 35. Desensitization to chemotherapeutic agents.
    Lieberman P; Castells M
    J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 37. Ongoing debate: anthracyclines and adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer.
    Mahesh S
    J Clin Oncol; 2012 Dec; 30(35):4445-6; author reply 4446. PubMed ID: 23071231
    [No Abstract]   [Full Text] [Related]  

  • 38. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
    Ewer MS; Ewer SM
    J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
    Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
    J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab cardiotoxicity in patients with breast cancer.
    Freitas AF; Rassi S
    Arq Bras Cardiol; 2014 Feb; 102(2):200. PubMed ID: 24676377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.